Artelo Biosciences, Inc. (ARTL) - חוב לטווח ארוך להון

This price chart, serving as confirmation of the market valuation, demonstrates the price action of Artelo Biosciences (ARTL), where the individual long-term debt-to-equity ratio stands at 0.00. Artelo Biosciences generates revenue by developing cannabinoid-based therapies to combat oncological pain syndromes and anxiety. The team brings together bold scientists developing innovative medical niches. The technology stack is complemented by automated data analysis systems and robotic molecule screening.

Assessing the reliability of equity assets begins with an analysis of the financing structure. This indicator measures the ratio of long-term liabilities to equity, determining the business's degree of dependence on borrowed funds. For Artelo Biosciences (ARTL), this is critical, as regulatory risks and clinical trial uncertainty limit access to low-cost financing. The history of long-term debt-to-equity allows for the identification of stagnation or aggressive scaling, while a stable trend confirms a balanced financial strategy.